ArticleOpen forum infectious diseases2025
Changes in Body Mass Index in Children and Adolescents Living With Human Immunodeficiency Virus in Europe and Thailand Starting Dolutegravir.
Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Excess weight gain has been reported in some adults on dolutegravir (DTG), but data in children/adolescents living with human immunodeficiency virus (CALHIV) are limited. Methods: CALHIV aged 2-17 years at DTG start from 15 observational cohorts across Europe and Thailand were included. Mixed models described changes in body-mass-index-for-age z-score (zBMI). We assessed (1) zBMI change 48 weeks before versus after DTG start; (2) zBMI change up to 96 weeks on DTG and associated factors; and (3) zBMI changes over 96 weeks in CALHIV aged 6-17 years at start of DTG versus protease inhibitor (PI)-based regimens using propensity score weighting. Results: Of 948 CALHIV on DTG (>99% HIV-1, <1% HIV-2), 50% were female, the median age was 13.7 (interquartile range [IQR], 11.1-15.6]) years, median zBMI was 0.31 (IQR, -0.64 to 1.19), 48% were Black, and 30% were overweight or obese at DTG start. Among 741 participants with zBMI available before and after DTG start, zBMI (95% confidence interval (CI) increased by 0.07 (.03-.11) versus 0.13 (.09-.16) ( Conclusions: CALHIV experienced zBMI increases on DTG with the largest gains in children aged 6-11 years, on TAF, with low baseline zBMI, and some variation by sex and ethnicity. However, zBMI changes over 96 weeks were comparable between those on DTG- and PI-based regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.